Heron Therapeutics (NASDAQ:HRTX) Stock Rating Upgraded by BidaskClub

BidaskClub upgraded shares of Heron Therapeutics (NASDAQ:HRTX) from a hold rating to a buy rating in a research report released on Wednesday, BidAskClub reports.

A number of other equities research analysts have also recently issued reports on HRTX. Evercore ISI reiterated a buy rating and issued a $75.00 target price on shares of Heron Therapeutics in a research note on Tuesday, August 13th. Northland Securities reiterated a buy rating and issued a $55.00 target price on shares of Heron Therapeutics in a research note on Monday, August 5th. ValuEngine upgraded Heron Therapeutics from a sell rating to a hold rating in a research note on Thursday, August 1st. Finally, Stifel Nicolaus reiterated a buy rating and issued a $38.00 target price on shares of Heron Therapeutics in a research note on Monday, August 5th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. Heron Therapeutics currently has a consensus rating of Buy and a consensus price target of $52.67.

HRTX stock opened at $19.41 on Wednesday. The company has a current ratio of 4.01, a quick ratio of 3.70 and a debt-to-equity ratio of 0.04. Heron Therapeutics has a 1 year low of $15.68 and a 1 year high of $33.20. The stock’s fifty day moving average is $18.20 and its two-hundred day moving average is $20.00.



Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Monday, August 5th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.02. The company had revenue of $36.66 million for the quarter, compared to analysts’ expectations of $31.04 million. Heron Therapeutics had a negative return on equity of 56.89% and a negative net margin of 172.07%. Equities analysts anticipate that Heron Therapeutics will post -2.73 earnings per share for the current year.

A number of hedge funds have recently bought and sold shares of the business. FMR LLC raised its stake in shares of Heron Therapeutics by 5.5% during the first quarter. FMR LLC now owns 8,473,847 shares of the biotechnology company’s stock valued at $207,101,000 after purchasing an additional 439,044 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Heron Therapeutics by 5.2% during the second quarter. Vanguard Group Inc. now owns 6,744,858 shares of the biotechnology company’s stock valued at $125,387,000 after purchasing an additional 330,351 shares in the last quarter. BlackRock Inc. raised its stake in shares of Heron Therapeutics by 0.9% during the second quarter. BlackRock Inc. now owns 4,901,392 shares of the biotechnology company’s stock valued at $91,116,000 after purchasing an additional 42,657 shares in the last quarter. Clearbridge Investments LLC raised its stake in shares of Heron Therapeutics by 153.4% during the first quarter. Clearbridge Investments LLC now owns 2,180,577 shares of the biotechnology company’s stock valued at $53,293,000 after purchasing an additional 1,320,025 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Heron Therapeutics by 60.2% during the second quarter. JPMorgan Chase & Co. now owns 1,425,517 shares of the biotechnology company’s stock valued at $26,274,000 after purchasing an additional 535,821 shares in the last quarter.

About Heron Therapeutics

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Featured Story: What is a support level?

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.